Injektions-/Infusionslösung clinical trials

An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient treatment modality in metastatic or advanced colorectal cancer (mCRC) patients with acquired FOLFIRI resistant cancer disease

This study looks at a new drug, SCO-101, combined with standard FOLFIRI chemotherapy for advanced bowel cancer that has stopped responding to FOLFIRI. Researchers want to see if the combination is safe, what dose works best, and if it helps shrink tumours.